Federal contract award
75N95024F00006
RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF INJECTABLE NALTREXONE AND MONTHLY INJECTABLE BUPRENORPHINE FOR COCAINE USE DISORDER (CTN-0109). AUGUST 15, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00006 (TO22).
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75N95022D00017 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $525.7K |
| Current contract value | $525.7K |
| Potential contract value / ceiling | $525.7K |
| Start date | Aug 15, 2024 |
| Current end date | Mar 31, 2026 |
| Potential end date | Mar 31, 2026 |
| Latest award activity | Aug 14, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 14, 2024 | 0 | $525.7K | RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF INJECTABLE NALTREXONE AND MONTHLY INJECTABLE BUPRENORPHINE FOR COCAINE USE DISORDER (CTN-0109). AUGUST 15, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00006 (TO22). |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.